To determine whether transplanted amniotic membrane mesenchymal stem cells (AMSCs) ameliorated the premature senescent phenotype of Bmi-1-deficient mice, postnatal 2-day-old Bmi-1 −/− mice were injected intraperitoneally with the second-passage AMSCs from amniotic membranes of β-galactosidase (β-gal) transgenic mice or wild-type (WT) mice labeled with DiI. Three reinjections were given, once every seven days. Phenotypes of 5-week-old β-gal + AMSC-transplanted or 6-weekold DiI + AMSC-transplanted Bmi-1 −/− mice were compared with vehicle-transplanted Bmi-1 −/− and WT mice. Vehicle-transplanted Bmi-1 −/− mice displayed growth retardation and premature aging with decreased cell proliferation and increased cell apoptosis; a decreased ratio and dysmaturity of lymphocytic series; premature osteoporosis with reduced osteogenesis and increased adipogenesis; redox imbalance and DNA damage in multiple organs. Transplanted AMSCs carried Bmi-1 migrated into multiple organs, proliferated and differentiated into multiple tissue cells, promoted growth and delayed senescence in Bmi-1 −/− transplant recipients. The dysmaturity of lymphocytic series were ameliorated, premature osteoporosis were rescued by promoting osteogenesis and inhibiting adipogenesis, the oxidative stress and DNA damage in multiple organs were inhibited by the AMSC transplantation in Bmi-1 −/− mice. These findings indicate that AMSC transplantation ameliorated the premature senescent phenotype of Bmi-1-deficient mice and could be a novel therapy to delay aging and prevent aging-associated degenerative diseases.
Growth retardation and premature aging were ameliorated by AMSC transplantation into
Bmi-1 −/− mice. Bmi-1 −/− mice had significantly decreased survival rates and body weight compared to WT mice ( Fig. 2A,B ). The overall sizes of the body, thymus, spleen and kidney were decreased in Bmi-1 −/− mice, compared with WT mice (Fig. 2C,D) . AMSC transplantation prolonged the median survival from 39 days to 92 days, and increased body weight, and overall size of the body, thymus, spleen and kidney in Bmi-1 −/− mice ( Fig. 2A-D) . These results demonstrated that AMSC transplantation ameliorated growth retardation and premature aging in Bmi-1 −/− mice.
To determine whether the rescue of growth retardation and premature aging in AMSC-transplanted Bmi-1 −/− mice was associated with cell proliferation and apoptosis, the thymus and kidney were examined by immunohistochemistry for Ki67 and caspase3 and by TUNEL staining. The results showed a decrease in the percentage of Ki67-positive thymocytes and renal cells and a significant increase in the percentages of caspase3-positive and TUNEL-positive thymocytes and renal cells in Bmi-1 −/− mice compared to WT mice. Compared to vehicle-transplanted Bmi-1 −/− mice, in AMSC-transplanted Bmi-1 −/− mice, the percentages of Ki67-positive thymocytes and renal cells were increased, however, the percentages of Caspase3-positive and TUNEL-positive thymocytes and renal cells were decreased significantly ( Figure E-J) . These results demonstrated that AMSC transplantation promoted cell proliferation and inhibited cell apoptosis in Bmi-1 −/− mice.
Decreased ratio of lymphocytic series was ameliorated by AMSC transplantation into Bmi-1 −/− mice.
To determine the proportion of peripheral blood cell series, blood cells were analyzed using a peripheral blood cell counter. The numbers of white blood cells, platelets and the ratio of lymphocytes relative to total white blood cells were decreased in Bmi-1 −/− mice compared to WT mice, whereas the ratio of neutrophils relative to total white blood cells was significantly increased. Compared with vehicle-transplanted Bmi-1 −/− mice, the ratio of lymphocytes relative to total white blood cells was increased in AMSC-transplanted Bmi-1 −/− mice (see Supplementary Table S1 online). These results demonstrated that AMSC transplantation increased the ratio of lymphocytic series relative to total white blood cells in Bmi-1 −/− mice. Dysmaturity of lymphocytic series was ameliorated by AMSC transplantation into Bmi-1 −/− mice. To investigate whether dysmaturity of T lymphocytes was ameliorated by AMSC transplantation into Bmi-1 −/− mice, CD4 and CD8 were measured in thymocytes and splenocytes. The ratio of CD4 − CD8 − thymocytes relative to total thymocytes was obviously increased, whereas the ratio of CD4 + CD8 + thymocytes relative to total thymocytes was significantly decreased in Bmi-1 −/− mice compared with WT mice ( Fig. 3A-C) . The ratios of CD4 − CD8 + and CD4 + CD8 − thymocytes relative to total thymocytes and CD4 + CD8 + , CD4 − CD8 + and CD4 + CD8 − splenocytes relative to total splenocytes were not altered ( Fig. 3A ,D-H). AMSC transplantation restored the ratios of CD4 − CD8 − or CD4 + CD8 + relative to total thymocytes in Bmi-1 −/− mice to WT ratios. These results demonstrated that AMSC transplantation ameliorated the dysmaturity of T lymphocytes in Bmi-1 −/− mice. To further observe B lymphocytes (B cells) development, B cells in bone marrow (BM) derived from hematopoietic stem cells were stained with B cell-surface markers B220, CD43, IgM and IgD. Splenetic B cells derived from immature B cells from BM were stained with IgM and IgD to classify them into developmental stages. B220 + IgM − CD43 + (pro-B), B220 + IgM − CD43 − (pre-B) and B220 + IgM + CD43 − (immature B) cells in BM and IgM + IgD − [transitional 1 (T1)-B] cells in spleens were decreased in Bmi-1 −/− mice compared to WT mice ( Fig. 4A ,C-F,J). The ratios of B220 high IgM + CD43 − (mature B) cells relative to total BM cells, and IgM + IgD + (T2-B) cells and IgM − IgD + (F0-B) cells relative to total cells in spleen were not altered significantly. AMSC transplantation restored the ratios of pro-B relative to total BM cells and T1-B cells relative to total splenocytes in Bmi-1 −/− mice to WT ratios ( Fig. 4B ,G-I). These results demonstrated that AMSC transplantation ameliorated the dysmaturity of B lymphocytes in Bmi-1 −/− mice. Impaired skeletal growth and development and premature osteoporosis were ameliorated by AMSC transplantation into Bmi-1 −/− mice. To assess whether the skeletal growth and development retardation were ameliorated by AMSC transplantation into Bmi-1 −/− mice, tibias were examined by radiography and micro-CT. Radiolucency of tibia was greater in Bmi-1 −/− mice compared to WT mice. From 3D reconstructed longitudinal sections and cross sections of the proximal ends of tibias, it can be seen that epiphyses were smaller, cortices were thinner, and trabecular bone volumes were lower in Bmi-1 −/− mice relative to WT mice. Compared with vehicle-transplanted Bmi-1 −/− mice, in AMSC-transplanted Bmi-1 −/− mice, radiolucency of tibia was lesser, epiphyses were larger, cortices were thicker, and trabecular bone volumes were increased significantly ( Fig. 5A,B ). These results demonstrated that AMSC transplantation ameliorated skeletal growth and development retardation.
To investigate whether the premature osteoporosis was ameliorated by AMSC transplantation into Bmi-1 −/− mice, osteoblastic bone formation and adipocyte formation-associated parameters were measured. Consistent with micro-CT analysis, trabecular bone volume, osteoblast number and protein levels of core binding factor alpha 1 (Cbfa1) and insulin-like growth factor 1 (IGF-1) were decreased significantly, whereas the number of adipocytes and protein levels of peroxisome proliferator-activated receptor γ (PPARγ ) were increased dramatically in Bmi-1 −/− mice compared to WT mice. Compared with vehicle-transplanted Bmi-1 −/− mice, in AMSC-transplanted Bmi-1 −/− mice, trabecular bone volume, osteoblast number and protein levels of Cbfa1 and IGF-1 were increased significantly, whereas the number of adipocytes and protein levels of PPARγ were decreased significantly ( Fig. 5C-J) . These results demonstrated that AMSC transplantation ameliorated the premature osteoporosis by increased osteoblastic bone formation and decreased adipocyte formation.
To determine if premature osteoporosis amelioration could be attributed to down-regulation of senescence-associated molecules in AMSC-transplanted Bmi-1 −/− mice, the protein expression levels of Wnt16, p16, p19, and p27 in bone tissue were measured. Results revealed that these protein expression levels were significantly up-regulated in Bmi-1 −/− mice compared with WT mice. Compared to vehicle-transplanted Bmi-1 −/− mice, in AMSCs-transplanted Bmi-1 −/− mice, the expression levels of Wnt16, p16, p19, and p27 were significantly down-regulated ( Fig. 5K,L) . These results demonstrated that AMSC transplantation ameliorated the premature osteoporosis associated with down-regulation of senescence-associated molecules in Bmi-1 −/− mice.
Migration, proliferation and differentiation of donor AMSCs in Bmi-1 −/− recipients. To exam-
ine whether donor AMSCs could migrate to various organs, genomic DNA and protein were isolated from the organs of vehicle-transplanted Bmi-1 −/− mice and AMSC-transplanted Bmi-1 −/− mice. The Bmi-1 gene were detected in the heart, liver, lung, kidney, bone marrow (BM) and thymus from Bmi-1 −/− AMSC transplant recipients, but not in the same organs from vehicle-transplanted Bmi-1 −/− mice. In contrast, neomycin (Neo), which replaced exon VII of the Bmi-1 gene in the Bmi-1 −/− mice, was detected in all organs (Fig. 6A ). The Bmi-1 protein was detected in bone, liver, kidney, thymus from Bmi-1 −/− AMSC transplant recipients, but almost not in the same organs from vehicle-transplanted Bmi-1 −/− mice, however, Bmi-1 protein expression levers were still lower in these organs from Bmi-1 −/− AMSC transplant recipients than these from vehicle-transplanted wild-type mice (Figs 5K,L and 6B,C). In contrast, p16 protein expression levels were significantly down-regulated in liver, kidney, muscle and thymus from Bmi-1 −/− AMSC transplant recipients compared with these from vehicle-transplanted Bmi-1 −/− mice ( Fig. 6B,D) . Bmi-1 positive cells were detected by immunohistochemistry in spleen, lung and bone marrow from vehicle-transplanted wild-type mice and Bmi-1 −/− AMSC transplant recipients, but almost not in the same organs from vehicle-transplanted Bmi-1 −/− mice, however, the percentage of Bmi-1-positive cells were 20.59%, 44.45% and 40.06% in spleen, lung and bone marrow from AMSC-transplanted Bmi-1 −/− mice relative to the these organs from vehicle-transplanted wild-type mice (Fig. 6E,F) . Moreover, β -gal + or DiI + donor AMSCs were identified in Bmi-1 −/− transplant recipients by immunohistochemistry and fluorescence microscopy. Diffusive β -gal + donor AMSCs in heart, liver, spleen, lung, kidney and thymus were detected in AMSC-transplanted Bmi-1 −/− mice, but not in vehicle-transplanted Bmi-1 −/− mice ( Fig. 6G,H) . DiI + donor AMSCs were observed under fluorescence microscopy in heart, liver, spleen, lung, kidney, skeletal muscle and thymus from AMSC-transplanted Bmi-1 −/− mice, but not vehicle-transplanted Bmi-1 −/− mice ( Fig. 7A,C) . These results demonstrated that donor AMSCs migrated and indirectly carried donor Bmi-1 into all tested organs, and delayed aging of organs in Bmi-1 −/− transplant recipients.
To assess whether increased proliferation is resulted from the contribution of transplanted AMSCs only or from an indirect effect on other cells, BrdU positive thymocytes and skeletal muscle cells were detected in DiI + AMSC-transplanted Bmi-1 −/− mice. The results showed the percentages of BrdU-positive skeletal muscle cells and thymocytes were decreased in Bmi-1 −/− mice compared to WT mice, and were increased in AMSC-transplanted Bmi-1 −/− mice compared to vehicle-transplanted Bmi-1 −/− mice ( Fig. 7B,E) . The percentages of BrdU positive cells in DiI + positive skeletal muscle cells and thymocytes were 42.59% and 23.20%, respectively, in AMSC-transplanted Bmi-1 −/− mice (Fig. 7B,F) . These results indicate that increased cell proliferation caused by AMSC transplantation was resulted from a direct effect of transplanted AMSCs and an indirect effect on other cells of organs.
To further observe whether donors AMSCs were differentiated into various tissue cells, tissue specific cell markers were identified in 6-week-old DiI + AMSC-transplanted Bmi-1 −/− mice. Results revealed that some donors AMSCs were differentiated into hepatocytes labeled with Albumin, or skeletal muscle cells and cardiocytes labeled with Desmin, or renal tubular epithelial cells labeled with E-cadherin, or satellite cells of skeletal muscle labeled with Pax7. Moreover, the percentage of Pax7-positive satellite cells of skeletal muscle was decreased in Bmi-1 −/− mice compared to WT mice, and were increased significantly in AMSC-transplanted Bmi-1 −/− mice compared to vehicle-transplanted Bmi-1 −/− mice (Fig. 7B,D) . These results demonstrated that donors AMSCs could differentiate into various tissue cells in Bmi-1 −/− transplant recipients.
Redox imbalance and DNA damage of multiple organs were ameliorated by AMSC transplantation in Bmi-1 −/− mice. To assess if redox imbalance of multiple organs was ameliorated by AMSCs migrating and differentiating into the multiple tissue specific cells and expressing antioxidase in Bmi-1 −/− mice, ROS and hydrogen peroxide (H 2 O 2 ) levels, catalase (CAT) and total-superoxide dismutase (T-SOD) activities were examined in heart, liver, spleen, lung, kidney, bone marrow and thymus; SOD2 positive area was detected in skeletal muscle in vivo, and T-SOD and CAT activities were examined in AMSCs conditioned medium (CM) and Control CM in vitro. The relative levels of intracellular ROS in all organs except heart, and H 2 O 2 in all organs were increased dramatically, whereas the relative activities of T-SOD and CAT in the organs were decreased significantly in Bmi-1 −/− mice compared to WT mice ( Fig. 8A-D) . Compared with vehicle-transplanted Bmi-1 −/− mice, the relative levels of intracellular ROS in all organs except heart and liver, and H 2 O 2 in all organs except liver were decreased significantly, whereas the relative activities of T-SOD in all organs except liver, and CAT in all organs except lung were increased significantly in AMSCs-transplanted Bmi-1 −/− mice ( Fig. 8A-D) . Moreover, the percentage of SOD2-positive area in skeletal muscles was decreased in Bmi-1 −/− mice compared to WT mice., and was increased significantly in AMSC-transplanted Bmi-1 −/− mice, compared to vehicle-transplanted Bmi-1 −/− mice and some donors AMSCs differentiated into skeletal muscle cells were expressing SOD2 (Fig. 7B,G) . When T-SOD and CAT activities were examined in AMSCs conditioned medium (CM) and control CM, results revealed that T-SOD and CAT activities were increased significantly in AMSCs CM compared to control CM (Fig. 8I) . These results demonstrated that the redox imbalance of multiple organs was ameliorated in Bmi-1 −/− mice by donor AMSC migrating and differentiating into the various tissue specific cells and expressing antioxidase.
To further determine if DNA damage of multiple organs was ameliorated in Bmi-1 −/− mice by AMSCs migrating into the organs, 8-hydroxydeoxyguanosine (8-OHdG) and γ -H2A.X were detected in bone marrow, spleen, lung and thymus. The results showed that the percentages of 8-OHdG-positive or γ -H2A.X-positive cells in bone marrow, spleen, lung and thymus were increased significantly in Bmi-1 −/− mice compared with wild-type mice, and were decreased dramatically in AMSC-transplanted Bmi-1 −/− mice compared with vehicle-treated Bmi-1 −/− mice ( Fig. 8E-H) . These results demonstrated that DNA damage of multiple organs was ameliorated in Bmi-1 −/− mice by donor AMSC migrating into the organs.
Discussion
In this study, we demonstrated that Bmi-1 deficiency resulted in growth retardation and premature aging because of decreased proliferation and increased apoptosis, decreased ratios and dysmaturity of lymphocytic series, impaired skeletal growth and development and premature osteoporosis associated with decreased osteoblastic bone formation, increased adipocyte formation and up-regulated senescence-associated molecules, and increased oxidative stress and DNA damage of multiple organs. Our results also demonstrated that these typical aging phenotypes in Bmi-1-deficient mice were largely rescued by transplanted AMSC through migrating, proliferating, expressing antioxidase, carried Bmi-1 and differentiated into multiple tissue cells in Bmi-1 −/− transplant recipients. These findings indicated that transplanted AMSCs had preventative and therapeutic potential for aging and aging-associated degenerative diseases.
The amniotic membrane, the innermost membrane surrounding the fetus, originates from embryonic epiblast cells before gastrulation. The membrane retains a pool of stem cells throughout pregnancy that contains epithelial stem cells derived from ectoderm and mesenchymal stem cells from the embryonic mesoderm 15, 16 . Consistent with previous reports on the characteristics of AMSCs 15,19-21 , the second-passage AMSCs we cultured from β -galactosidase (β -gal) transgenic mice exhibited plastic adherence and fibroblast-like morphology. They possessed multiple differentiation potentials toward osteoblasts and adipocytes, and high expressed defined mesenchymal stem cell markers with low expression of embryonic stem cell markers. The AMSCs showed little expression of hematopoietic stem cell markers. Thus, the second-passage AMSCs had good stem cell potential.
Currently, anti-aging therapy with stem cells as a regenerative medical treatment is proposed as the most effective way to delay senescence. Previous studies suggest that accumulated metabolic stress and impaired function of adult stem cells in vivo are critical for the initiation and development of aging and aging-associated degenerative diseases 14 . Transplanted stem cells are considered promising candidate cells for regenerative applications based on their high proliferative and differentiated capacity and paracrine effects 22 . Previous studies suggest that transplanted AMSCs migrate into injured tissues or organs and differentiate into cells such as cardiocytes, liver cells, and neurocytes and ameliorate myocardial infarction 23 , liver cirrhosis 24 and Parkinson's disease 21 .
Bmi-1, derived from the polycomb family, inhibits space-specific and time-specific expression of the Hox gene in growth and development. Bmi-1 systematic deficiency leads to shortened life span and growth retardation 7, 8 . Consistent with these results, we found that Bmi-1 deficiency led to shortened survival rates, and decreased body weight and overall size of the body, thymus, spleen and kidney. We found that AMSC transplantation prolonged survival, increased body weight and overall sizes of the body, thymus, spleen and kidney directly by promoting cell proliferation and inhibiting cell apoptosis in Bmi-1 deficient mice. Thus, AMSC transplantation rescued the shortened life span and growth retardation in a model of systematic senescence.
Previous observations suggest that Bmi-1 deficiency leads to an abnormal hematological system phenotype 25 . Our study further demonstrated a decreased number of white blood cells, platelets and a decreased ratio of lymphocytes relative to total white blood cells, and increased the ratio of neutrophils relative to total white blood cells in Bmi-1 deficient mice. AMSC transplantation significantly increased the ratio of lymphocytic series relative to total white blood cells. Thus, AMSC transplantation partially rescued abnormal peripheral blood cell parameters. The decreased overall size of the thymus reflects immunosenescence. Maturation of T lymphocytes occurs in the thymus, which is a differentiated development site 26 . Immature T lymphocytes migrate from bone marrow to thymus, as CD4 and CD8 double-negative cells. Development continues through the CD4 and CD8 double-positive stage, and later to mature single-positive CD4 or CD8 T lymphocytes 27 . Several lines of evidence indicate that Bmi-1-deficient mice have defects in thymocyte maturation 12, 28 . Consistent with these results, we found that Bmi-1 deficient mice had decreased CD4 and CD8 double-positive thymocytes and increased CD4 and CD8 double-negative thymocytes. AMSC transplantation significantly increased CD4 and CD8 double-positive thymocytes and decreased CD4 and CD8 double-negative thymocytes in Bmi-1-deficient mice, but did not return them to normal levels. Immunosenescence-related changes indicate a developmental barrier of B lymphocytes that is renewed from hematopoietic stem cells in bone marrow 26 . The developmental stages of bone marrow B lymphocytes are pro-B cells, pre-B cells, immature B cells and mature B cells. Following early development in bone marrow, developing B lymphocytes migrate to populate the spleen where they undergo further maturation 27, 29 . When fewer pro-B cells are generated and fewer of these cells transit into subsequent differentiation steps, a lower number of mature B cells leave the bone marrow 26 . Peripheral immature B cells in spleen derived from bone marrow are defined as transitional B cells which include transitional 1 (T1) phase B (T1-B) cells and T2-B cells according to different phenotypic and functional characteristics 30 . Bmi-1 deficiency down-regulates the self-renewal capacity of hematopoietic stem cells and leads to hematopoietic defects 10 . Whether the developmental barrier of B lymphocytes exists in Bmi-1-deficient mice is unclear. We found that pro-B cells, pre-B cells and immature B cells in bone marrow and T1-B cells in spleen were decreased in Bmi-1-deficient mice compared to WT mice. Whereas, AMSC transplantation significantly increased pro-B cells and T1-B cells in Bmi-1-deficient mice. Our results suggest that AMSC transplantation promoted maturation of B cells to T1-B cells in spleen. Therefore, AMSC transplantation partially ameliorated the dysmaturity of T and B lymphocytes caused by hematopoietic defects in Bmi-1 deficiency.
Our previous results demonstrated that Bmi-1 deficiency leads to aging-associated osteoporosis, as determined by down-regulated self-renewal capacity of bone marrow mesenchymal stem cells 8 . The recent literature has evidence suggesting that transplanted young mesenchymal stem cells significantly slow the loss of bone density and prolong the life span of old mice 31 . Cbfa1, the unique osteogenesis-specific transcription factor, is closely involved in growth and development of bone 32 . IGF-1 is a critical mediator for longitudinal bone growth, skeletal maturation, and bone mass acquisition during growth and during the maintenance of bone in adult life 33 . PPARγ is a critical transcription factor involved in adipogenic differentiation 34 . In this study, we found that Bmi-1 deficiency led to decreases in trabecular bone volume, number of osteoblasts and protein levels of Cbfa1 and IGF-1; and increased numbers of adipocytes with higher PPARγ protein levels. AMSC transplantation ameliorated these effects. Results from this study indicate that AMSC transplantation rescued aging-associated osteoporosis by promoting osteogenesis and inhibiting adipogenesis.
Previous studies demonstrated that Wnt16, a senescent marker, is over-expressed in cells undergoing stress-induced premature senescence and oncogene-induced senescence. Wnt16 is necessary to initiate replicative senescence 35 . We found that Wnt16 protein was up-regulated in Bmi-1-deficient bone and was down-regulated by AMSC transplantation. Bmi-1 is involved in cell cycle regulation, self-renewal of stem cells and cell senescence by inhibiting the p16 INK4a /Rb, p19 AFR /p53 and p27 pathways [8] [9] [10] . Whether aging-associated osteoporosis rescued by AMSC transplantation is associated by down-regulation of cyclin kinase inhibitors is unclear. We found that expression of p16, p19 and p27 was significantly down-regulated in AMSC-transplanted Bmi-1-deficient bone. Our results suggest that AMSC transplantation is critical for preventing aging-associated osteoporosis by inhibiting Wnt16, p16, p19 and p27.
β -gal, encoded by the bacterial gene LacZ, is an effective molecular marker for tracing the migration, distribution, proliferation, and differentiation of donor cells in vivo to study their effects on tissue repair following injury 36 . DiI, a fluorescent membrane dye, represents a non-toxic, highly stable, and efficient method suitable for steady tracing of mesenchymal stem cells in host 37 . In this study, we used AMSCs derived from β -gal transgenic mice or derived from WT mice labeled with DiI as donor cells transplantated into Bmi-1-deficient mice via the intraperitoneal injection. We found that β -gal-positive or DiI positive donor AMSCs migrated into all examined organs including heart, liver, spleen, lung, kidney, skeletal muscle and thymus. Transplanted AMSCs have the capacity to proliferate and promote proliferation of surrounding other cells of organs in Bmi-1 −/− transplant recipients. Our previous results showed that AMSCs derived from β -gal transgenic mice that were subcutaneously transplanted into wild-type mice and differentiated into neuroglial cells and oligodendroglial cells 38 . In this study, we demonstrated that donor AMSCs were differentiated into hepatocytes, skeletal muscle cells, cardiocytes, renal tubular epithelial cells, and satellite cells of skeletal muscle in Bmi-1-deficient recipients. Thus we believe that some transplanted cells still maintained stem cell characterization, other of them had differentiated into tissue specific cells, which explains the later decline in the transplanted mice. β -gal transgenic AMSCs expressing the Bmi-1 gene and protein were transplanted into Bmi-1-deficient mice. The Bmi-1 gene and protein were also used as markers to track the distribution of donor cells in Bmi-1-deficient recipients. The Bmi-1 gene and protein were expressed in tissues or organs of viable Bmi-1-deficient recipients, including heart, liver, spleen, lung, kidney, bone marrow and thymus. And the protein level of p16 was significantly down-regulated in these multiple tissues from AMSCs-transplanted Bmi-1-deficient mice compared to vehicle-transplanted Bmi-1-deficient mice. These results suggest that AMSCs can transfer into multiple tissues through circulation, proliferate and differentiate into the mature cells of various tissues to play a direct role in delaying premature aging through inhibiting p16 in Bmi-1 deficient recipients.
The free radical theory suggests that ROS accumulation leads to senescence. T-SOD and CAT, the key antioxidant enzymes, constitute a defense system against oxidative stress injury and reduce O 2 − to H 2 O 2 and water 6, 7 . Consistent with our previous results that AMSC transplantation decreased CCl 4 -induced hepatocyte senescence by depressing oxidative stress 24 , recent studies suggest that transplantation of adipose-derived stem cells might contribute to the regeneration of senescent skin by anti-oxidation 22 . Several lines of our previous evidence suggest that Bmi-1 deficiency leads to redox imbalance and antioxidants rescue the premature senescent phenotype by maintaining redox balance 7 . In this study, we found that AMSC transplantation decreased intracellular ROS and H 2 O 2 levels and increased the activities of T-SOD and CAT in multiple organs of Bmi-1-deficient mice. These results suggested that AMSC transplantation improved the redox balance of multiple organs in Bmi-1-deficient recipients. Previous observations demonstrated that activated SOD and CAT can be expressed by rat mesenchymal stem cells and human bone marrow stroma cells under conditions in which ascorbic acid is added 39, 40 . The mechanisms by which AMSC transplantation maintains redox balance might include 1) directly expressing antioxidant enzymes for scavenging ROS, or 2) indirectly carrying donor Bmi-1 to maintain redox balance. In this study, we found that donor AMSCs were migrating and differentiating into the various tissue specific cells and expressing SOD2, and increasing the SOD2 levels of overall cells from recipient in vivo; AMSCs also could secrete anti-oxidase T-SOD and CAT in vitro. Previous observations have demonstrated that oxidative stress can trigger activation of the DNA damage response (DDR) pathway 41 . Our previous studies also demonstrated that DNA damage occurred in Bmi-1 deficient mice caused by oxidative stress, including significant increases of 8-OHdG and γ -H2A.X -positive cells 7 . The current study demonstrated that DNA damage of multiple organs was ameliorated by AMSCs migrating into the organs in Bmi-1 −/− mice. However, the exact mechanism by which AMSC transplantation maintains redox balance and prevents DNA damage remains to be investigated.
In conclusion, transplanted AMSCs could migrate into multiple organs, proliferate, express antioxidase, carry Bmi-1 and differentiate into various tissue cells, promote growth and delay senescence by stimulating proliferation and inhibiting apoptosis; increase the ratio of lymphocytes among white blood cells by improving the dysmaturity of lymphocytic series; ameliorate impaired skeletal growth and development and premature osteoporosis by promoting osteogenesis, inhibiting adipogenesis and down-regulating senescence-associated molecules; inhibit oxidative stress and DNA damage of multiple organs in vehicle-transplanted Bmi-1 −/− mice. Results from this study indicate that transplanted AMSCs ameliorated the premature senescent phenotype of Bmi-1 deficient mice. Our findings implied that AMSC transplantation will be a novel therapeutic way to delay aging and prevent aging-associated degenerative diseases.
Experimental Procedures
Mice and genotypingN. Bmi-1 homozygotes (Bmi-1 −/− ) and wild-type (WT) littermates were generated and genotyped as described previously 7, 8 . Adult β -galactosidase (β -gal) transgenic mice were obtained from the Jackson Laboratory (Bar Harbor, Maine, USA). Postnatal 2-day-old Bmi-1 −/− mice and WT littermates were used as recipients. β -gal transgenic mice and WT mice in the middle and late phases of normal pregnancy were used as donors 36 . Especially, AMSCs derived from WT mice were labeled with DiI (Sigma-Aldrich, Saint Louis, Missouri, USA) for cell tracking according to the manufacturer's protocol before the transplantation following previously described methods 24, 37 .
This study was carried out in strict accordance with the guidelines of the Institute for Laboratory Animal Research of Nanjing Medical University. The protocol was approved by the Committee on the Ethics of Animal Experiments of Nanjing Medical University (Permit Number: BK2006576) 7 .
AMSC cultures and harvesting. Amniotic membranes were separated from chorion using blunt dissection and rinsed in phosphate buffered saline (PBS) containing penicillin and streptomycin (200 U ml −1 penicillin and 200 μ g ml −1 streptomycin) 3 times. Amniotic membranes were minced and digested for 55 minutes in 0.05% trypsin-0.02% EDTA solution at 200 rpm min −1 in a constant temperature shaker at 37 °C and centrifuged. Supernatants were discarded and pellets were washed with PBS and centrifuged repeatedly. Pellets were resuspended in 10 ml normal culture medium of α -MEM containing 15% (v/v) fetal bovine serum, 200 U ml −1 penicillin, 200 μ g ml −1 streptomycin, 2 mM L-glutamine and 50 μ g ml −1 ascorbic acid in 10 cm petri dishes and kept in a humidified 5% CO 2 incubator at 37 °C. Half of the medium was changed every 3 days. At 90% confluence, cells were recovered using 0.25% trypsin-0.02% EDTA for expansion. Second-passage AMSCs were used.
Osteogenic differentiation of AMSCs. To identify osteogenic differentiation, second-passage AMSCs were cultured for 14 days in 10 ml osteogenic medium of α -MEM containing 15% (v/v) fetal bovine serum, 10 −8 M dexamethasone and 50 μ g ml −1 ascorbic acid in 10 cm petri dishes in a humidified 5% CO 2 incubator at 37 °C. Medium was changed every three days. Cellular alkaline phosphatase (ALP) cytochemistry staining was performed following previously described methods 42 .
AMSCs conditioned medium preparation. At 90% confluence, normal culture medium was discarded, and the adherent second-passage AMSCs were washed with PBS and transparent medium of α -MEM (Gibco Life Technologies, Grand Island, NY, USA) for 3 times respectively. The adherent second-passage AMSCs were cultured with 6 ml transparent medium of α -MEM in 10 cm petri dishes and kept in a humidified 5% CO 2 incubator at 37 °C for 24 hours. The supernatant were collected, filtered with 0.22 μ m filter (Millipore, Billerica, MA, USA) for removing cell fragments, ultrafiltered with Amicon Ultra-15 Centrifugal Filter (molecular weight cutoff 3KDa) (Millipore, USA) in 4 °C centrifuge at 4000 rpm for 2.5 hours, and concentrated to the original volume 1/10 as AMSCs conditioned medium (AMSCs CM). Transparent medium of α -MEM was ultrafiltered and concentrated as Control CM. Cellular LacZ staining for β-gNalactosidase activity. Cellular LacZ staining was performed following a modified version of a previously described method 36, 43 . Briefly, AMSCs were fixed with PLP fixative (4% paraformaldehyde containing 0.075 M lysine and 0.01 M sodium periodate solution) 45 minutes at 4 °C. Following fix, AMSCs were washed three times for 30 minutes in LacZ wash buffer [2 mM MgCl 2 , 0.01% sodium deoxycholate, 0.02% Nonidet-P40 (NP-40) in PBS, PH7.3]. Staining was carried out in 0.5 mg ml −1 X-gal, 5 mM potassium ferrocyanide, and 5 mM potassium ferricyanide in LacZ wash buffer at 37 °C overnight protection from light. AMSC transplantation. AMSCs (total 1.0 × 10 7 cells in 0.1 ml α -MEM) were intraperitoneally injected into the postnatal 2-day-old Bmi-1 −/− mice (Bmi-1 −/− + AMSCs) with a 31-gauge needle and reinjected once every 7 days for 3 times. Bmi-1 −/− and WT control group were established by injection of the same volume of α -MEM into the peritoneal cavity.
BrdU incorporation. BrdU (Sigma-Aldrich, USA), the thymidine analog that incorporates into the DNA of dividing cells during S phase, was used for mitotic labeling. Briefly, BrdU was dissolved freshly in 0.9% saline to make 10 mg/ml solution just before injection. Mice were intraperitonealy given thrice injections of BrdU solution (50 mg kg −1 ) with interval of 6 hours before histology analysis 44 .
Histology analysis. Phenotypes of 5-week-old β -gal + AMSC-transplanted or 6-week-old DiI + AMSC-transplanted Bmi-1 −/− mice were compared with vehicle-transplanted Bmi-1 −/− and wild-type mice. Mice were anesthetized with 3% pentobarbital sodium (40 mg kg −1 ) and perfused with 100 ml normal sodium, then perfused and fixed with PLP fixative. Heart, liver, spleen, Lung, kidney, muscle and thymus were dissected.
For histochemistry or immunohistochemistry, some sections were dehydrated in a series of graded ethanol solutions and embedded in paraffin and 5 μ m sections were cut on a rotary microtome (Leica Microsystems Nussloch GmbH, Nubloch, Germany) 36 . Especially, tibiae were removed, fixed, decalcified, dehydrated, embedded and stained histochemically for total collagen or hematoxylin and eosin (HE) as in previously described methods 8 .
For immunofluorescence, some sections were dehydrated in 20% and 30% sucrose solution at 4 °C for 48 h respectively, and cut transversely on a freezing microtome at 5 μ m thickness (Leica, Germany).
Skeletal radiography and Micro-computed tomography (Micro-CT). Femurs were removed
and dissected free of soft tissue. Contact radiographs were taken using a Faxitron Model 805 radiographic inspection system (Faxitron Contact, Faxitron, Germany; 22 kV and 4-minute exposure time) as described previously 8 . Micro-CT was taken with a SkyScan 1072 scanner and associated analysis software (SkyScan, Antwerp, Belgium) as described previously 8 . Briefly, image acquisition was performed at 100 kV and 98 mA with a 0.9-degree rotation between frames. 2D images were used to generate 3D renderings using the 3D Creator software supplied with the instrument. The resolution of the Micro-CT images is 18.2 μ m.
Immunocytochemical or immunohistochemical staining. For immunocytochemical staining, cells seeded on coverslips were fixed with PLP solution for 45 minutes and preincubated with serum. Primary antibodies against CXCR4 (Abcam, Cambridge, Massachusetts, USA) and corresponding affinity-purified Texas Red (TXRD)-conjugated secondary antibody (Santa Cruz Biotechnology Inc., Dallas, Texas, USA) were used. Nuclei were labeled by 4' , 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, USA) and mounted with medium that prevented fluorescence quenching (Vector Laboratories Inc., Burlingame, California, USA) 7 .
Immunohistochemical staining was performed following previously described methods 7, 8, 36 . Serial paraffin sections were deparaffinized, dehydrated, and, for antigen retrieval, steamed for 20 minutes in PBS (0.01 mM pH 7.4) followed by blocking of endogenous peroxidase (3% H 2 O 2 ) and preincubation with serum. Primary antibodies against Ki67 (Abcam, USA), Caspase3 (Cell signaling Technology, Beverly, Massachusetts, USA), β -galactosidase (Abcam, USA), Bmi-1 (Millipore, Billerica, Massachusetts, USA), 8-hydroxyguanosine (8-OHdG) (Abcam, USA), γ -H2A.X (Ser139) (Cell Signaling Technology, USA), Albumin (Abcam, USA), Desmin (Thermo Fisher, Rockford, Illinois, USA), E-cadherin (Santa Cruz Biotechnology, USA), Pax7 (Proteintech Group Inc., Chicago, Illinois, USA), BrdU (Millipore, USA) and superoxide dismutase 2 (SOD2) (Novus Biological, Littleton, Columbia, USA), were used. After
